Neurocrine Biosciences (NASDAQ:NBIX) inks an agreement with Takeda Pharmaceutical Company Limited (NYSE:TAK)
for exclusive rights to seven Takeda programs in psychiatry, including
three clinical-stage assets for the potential treatment of schizophrenia
(TAK-831), treatment-resistant depression (TAK-653) and anhedonia
(inability to feel pleasure) (TAK-041).
Under the terms of the deal, NBIX will be
responsible for development and commercialization. Takeda will receive
$120M upfront, up to $495M in development milestones, up to $1.4B in
commercial milestones and double-digit royalties on net sales. Takeda
has the option to opt in or out of a 50/50 profit share on all clinical
programs at certain points in development.
NBIX will host a conference call momentarily to discuss the agreement.
https://seekingalpha.com/news/3583358-neurocrine-bio-inks-deal-takeda-for-psychiatry-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.